N
O7PA
vs
D
DAX Index
Over the past 12 months, O7PA has underperformed DAX Index, delivering a return of 0% compared to the DAX Index's +24% growth.
Stocks Performance
O7PA vs DAX Index
Performance Gap
O7PA vs DAX Index
Performance By Year
O7PA vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
NeuBase Therapeutics Inc
Glance View
NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 33 full-time employees. The firm is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA) and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type one disease mRNA.